ALPS Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

ALPS Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-65,860	Closed	-$3.59M	–	987
2018 Q3	$3.59M	Buy	65,860 +12,152	+23%	+$831K	0.02%	186
2018 Q2	$4.45M	Buy	53,708 +4,076	+8%	+$315K	0.03%	177
2018 Q1	$3.31M	Buy	49,632 +9,136	+23%	+$528K	0.03%	172
2017 Q4	$2.08M	Buy	40,496 +5,215	+15%	+$375K	0.01%	194
2017 Q3	$3.15M	Buy	35,281 +7,184	+26%	+$545K	0.02%	163
2017 Q2	$1.68M	Buy	28,097 +1,624	+6%	+$90.8K	0.01%	193
2017 Q1	$1.41M	Sell	26,473 -3,100	-10%	-$184K	0.01%	193
2016 Q4	$1.48M	Sell	29,573 -9,463	-24%	-$507K	0.01%	193
2016 Q3	$2.35M	Buy	39,036 +547	+1%	+$31.5K	0.02%	175
2016 Q2	$1.97M	Buy	38,489 +8,041	+26%	+$344K	0.02%	170
2016 Q1	$899K	Sell	30,448 -2,107	-6%	-$66.5K	0.01%	191
2015 Q4	$1.48M	Sell	32,555 -5,860	-15%	-$307K	0.01%	191
2015 Q3	$1.6M	Buy	38,415 +14,086	+58%	+$735K	0.02%	184
2015 Q2	$1.47M	Buy	+24,329	New	+$1.61M	0.01%	187

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ALPS Advisors's ONCE Position: Q4 2018 in Review

ALPS Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 65,860 shares — an estimated $3.59M sold.

ALPS Advisors first reported a position in ONCE in Q2 2015 and held it in 14 quarters. The position peaked at $4.45M in Q2 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

ALPS Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
ALPS Advisors sold 65,860 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $3.59M.
ALPS Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 14 quarters.
ALPS Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $4.45M in Q2 2018.
157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.